Threat Interpretation Bias as Cognitive Marker and Treatment Target in Pediatric Anxiety: R33 Phase
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Michelle Rozenman, Ph.D.
- Número de teléfono: 303-871-6448
- Correo electrónico: bravelab@du.edu
Ubicaciones de estudio
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80210
- Reclutamiento
- University of Denver
-
Investigador principal:
- Michelle Rozenman, Ph.D.
-
Contacto:
- Michelle Rozenman, Ph.D.
- Número de teléfono: 303-871-6448
- Correo electrónico: bravelab@du.edu
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Provision of signed and dated informed consent form by parent/legal guardian and signed youth assent. If youth turns 18 after study entry (i.e., Visit 1), they will need to reconsent as an adult to continue participation. Youth and consenting parent/legal guardian agree to 6-week study participation as part of consent/assent process.
- Youth and parent/legal guardian speak sufficient English to engage in study procedures.
- Youth is aged 10 to 17 inclusive, at time of signing consent/assent and completion of Visit 1 procedures.
- Youth meets full diagnostic criteria for primary Generalized Anxiety Disorder, Separation Anxiety Disorder, or Social Anxiety Disorder as assessed by the Anxiety Disorders Interview Schedule-IV (ADIS-IV) during Visit 1. Note: the ADIS diagnostic criteria are only valid for two weeks. For the purposes of our study, a youth should be randomized, have randomization revealed, and be in treatment (i.e., complete Visit 2) within 14 days of Visit 1 diagnostic/clinical interview. If this timeline is not met, clinical measures may need to be updated with the youth and parent/legal guardian, although consent does not need to be re-obtained. Parent and youth versions of the Screen for Child Anxiety Related Emotional Disorders, as well as the Pediatric Anxiety Rating Scale and Clinician's Global Impressions - Severity/Improvement Scale might also be re-administered. The ADIS will need to be reviewed to assess whether there have been any diagnostic changes during the elapsed time period. If more than one month has elapsed from the time of baseline, all measures within baseline procedures would be readministered, including reconsenting parent/legal guardian and youth. All such cases must be triaged in the next immediate weekly Project Management meeting.
- Youth otherwise meeting study entry criteria, who are receiving treatment for a stable medical or psychiatric condition, may be included providing that medication and dose have been stable for at least six weeks (e.g., stable dose of stimulant medication for Attention-Deficit/Hyperactivity Disorder) prior to study entry and remain stable on that medication and dose throughout their study participation. Changes to medication during study participation following randomization at Visit 2 will be considered non-urgent protocol deviations and will be tracked in the Protocol Deviations Form. Youth would not be removed from the study in this case, but their data may be excluded from sensitivity analyses.
- Youth must have a standard score of at least 85 on the Wechsler Abbreviated Scale of Intelligence, Vocabulary and Matrix Reasoning subtests, as well as the Wide Range Achievement Test-4 Reading subtest (administered during Visit 1) to ensure ability to read and understand stimuli during interpretation bias assessments and CBM-I.
- Youth must have access to a desktop or laptop computer and access to internet at home or can access one at their school or local library for the at-home portion of the computer training program. For youth without access, families can agree to complete all 16 CBM-I trainings (if randomized to CBM-I) at the BRAVE Lab.
Exclusion Criteria:
- Requires treatment other than CBM-I/CR: namely, youths with severe anxiety indicating need for higher level of care (e.g., psychiatric hospitalization), or primary major depressive disorder, bipolar disorder, psychosis, safety concerns due to recent or current acute suicidal ideation with plan, intent, and/or attempt that warrants alternate intervention, Posttraumatic Stress Disorder, substance dependence, current physical or sexual abuse, or intellectual disability. This will be determined during the Visit 1 ADIS interview. Consultation with the PI will occur in all cases where another mental health concern may be primary and/or warrant more immediate treatment.
- At Visit 1, is currently in alternate psychosocial intervention for any reason or has plans to initiate any psychosocial intervention for any reason.
- Has previously received any type of cognitive bias modification (attention or interpretation bias as target) at the BRAVE Lab or elsewhere.
- The family indicates they are no longer interested or able to participate in the study after Visit 1 (in which it is determined that the family is eligible) but before the family is randomized or told of their randomization. The youth will be excluded and not included in ITT analyses, and the randomization will be "thrown back" into the randomization scheme.
- Has significant uncorrected vision impairment (e.g., uncorrected blindness) that precludes participation in the computerized assessment and intervention components of the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Modificación del Sesgo Cognitivo para Interpretaciones (CBM-I)
Intervención computarizada de 16 sesiones dirigida a reducir el sesgo de interpretación.
En este estudio, CBM-I se personaliza para los síntomas de ansiedad de los jóvenes.
Durante las sesiones de CBM-I, los jóvenes indican si los pares de palabras y oraciones están relacionados y reciben comentarios destinados a reducir el sesgo.
|
Computerized intervention in which youth see word-sentence pairs personalized to their anxiety symptoms, and indicate whether these are related.
Youth receive feedback aimed to reduce interpretation b
Otros nombres:
|
|
Comparador activo: Cognitive Restructuring (CR)
Four session psychosocial intervention aimed at reducing anxiety.
CR is a standard treatment technique (and often full intervention protocol) aimed at modifying anxious cognitions by teaching youth to identify when they make threat attributions, consider alternate non-threatening attributions, and thereby change their anxious thought processes, resultant avoidance, and anxiety symptoms.
|
Adapted from well-tested manual, The Coping Cat (child and adolescent versions), administered by trained, supervised therapists.
Duration of CR is matched to CBM-I in regard to total time in intervention across four weeks.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Linguistic Interpretation Bias as Assessed by the Word-sentence Association Paradigm for Youth (WSAP-Y)
Periodo de tiempo: 6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
The WSAP-Y is a computerized assessment of interpretation bias in which youth indicate whether word-sentence pairings are related.
This measure provides information about the degree to which youth evidence interpretation bias, as well as a behavioral (reaction time) index for bias endorsement.
For the primary outcome of percent threat interpretations endorsed, the possible range is 0 (zero) to 100%.
Higher percentage indicates more threat interpretation bias (i.e., the youth endorsed a higher proportion of threat words as related to ambiguous sentences); lower scores indicate lower threat interpretation bias.
Greater decrease in the percent of threat interpretations endorsed and lower absolute scores indicate "better" outcome (i.e., more reduction in threat interpretation bias; less interpretation bias overall).
|
6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
|
Change in Visual Interpretation Bias as Assessed by the Ambiguous Faces Task
Periodo de tiempo: 6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
Youth view faces portraying neutral expressions or subtle emotional expressions (i.e., morphed faces ranging in intensity of emotional valence).
Youth categorization of faces as neutral or threatening provides their sensitivity and bias for reporting presence of threat.
The criterion mean value in outcomes below reflects a score from -1 to 1, with higher negative numbers reflecting greater bias toward angry faces, and higher positive values approaching one reflecting a bias toward happy faces.
Theoretically, higher positive values indicate "better" outcome such that youth have more positive bias toward facial stimuli.
|
6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
|
Change in Self-reported Interpretation Bias as Measured by the Children's Automatic Thoughts Scale (CATS)
Periodo de tiempo: 6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
The Children's Automatic Thoughts Scale is a youth self-report questionnaire which assesses presence and frequency of a variety of anxious thoughts from domains of: physical threat, social threat, personal failure, and anxious hostility.
Total scores range from 0 to 160, with higher scores indicating more threat interpretation bias.
Higher scores indicate "worse" outcome, or that youth self-report that they have more threatening thoughts and/or threatening thoughts at higher frequency; lower scores indicate "better" outcome or that youth self-report fewer threatening thoughts and/or threatening thoughts at lower frequency.
|
6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of CBM-I Trainings Completed of 16 Intended Sessions (CBM-I Arm Only)
Periodo de tiempo: 6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
This outcome is related to the "feasibility of CBM-I" aim.
The number of CBM-I trainings completed of 16 intended sessions.
Theoretically, completion of more training sessions is better and indicates that youth received a higher "dose" of training.
This outcome only applies to the CBM-I arm.
|
6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
|
Participant/Parent Acceptability Questionnaire (PAQ)
Periodo de tiempo: 6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
The Participant Acceptability Questionnaire is a 8-item youth and parent report questionnaire, accompanied by an exit interview, that assesses burden (travel, boredom), credibility of computerized intervention techniques, and youth comprehension of the intervention.
Parents and youth complete the PAQ separately.
|
6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
|
Anxiety symptom severity - PARS
Periodo de tiempo: 6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
Anxiety symptom severity as measured by clinician-administered Pediatric Anxiety Rating Scale (PARS).
Administered separately to parent and child, and scored by clinician by summing totals for the 7 items.
Scores range from 0-35, with higher scores suggesting higher/worse anxiety symptom severity.
|
6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
|
Anxiety symptoms - SCARED
Periodo de tiempo: 6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
Total anxiety symptoms as measured by the Screen for Anxiety Related Emotional Disorders (SCARED), 41-item version.
Each of 41 items ranges from 0-2, total anxiety symptoms calculated by scoring total across all 41 items.
Total scores range from 0-82, with higher scores suggesting more/worse anxiety symptoms.
|
6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 5R33MH121552 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Marco de tiempo para compartir IPD
Criterios de acceso compartido de IPD
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .